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An increasing proportion of cognitive difficulties are recognised to have a functional cause, the 
chief clinical indicator of which is internal inconsistency. When these symptoms are impairing 
or distressing, and not better explained by other disorders, this can be conceptualised as a 
cognitive variant of Functional Neurological Disorder (FND), termed Functional Cognitive 
Disorder (FCD). FCD is likely very common in clinical practice but may be under-
diagnosed. Clinicians in many settings make liberal use of the descriptive term Mild Cognitive 
Impairment (MCI) for those with cognitive difficulties not impairing enough to qualify as 
dementia. However, MCI is an aetiology-neutral description, which therefore includes patients 
with a wide range of underlying causes. Consequently, a proportion of MCI cases are due to 
non-neurodegenerative processes, including FCD. Indeed, significant numbers of patients 
diagnosed with MCI do not "convert" to dementia. The lack of diagnostic specificity for MCI 
"non-progressors" is a weakness inherent in framing MCI primarily within a deterministic 
neurodegenerative pathway. It is recognised that depression, anxiety and behavioural changes 
can represent a prodrome to neurodegeneration; empirical data are required to explore whether 
the same might hold for subsets of people with FCD.  Clinicians and researchers can improve 
study efficacy and patient outcomes by viewing MCI as a descriptive term with a wide 
differential diagnosis, including potentially reversible components such as FCD. We present a 
preliminary definition of Functional Neurological Disorder- Cognitive Subtype, explain its 
position in relation to other cognitive diagnoses and emerging biomarkers, highlight clinical 
features that can lead to positive diagnosis (as opposed to a diagnosis of exclusion), and red 
flags that should prompt consideration of alternative diagnoses. In the research setting, positive 
identifiers of FCD will enhance our recognition of individuals who are not in a 
neurodegenerative prodrome, while greater use of this diagnosis in clinical practice will 
facilitate personalised interventions.  
 
Abbreviations: 
FCD: Functional Cognitive Disorder 
MCI: Mild Cognitive Impairment 




DSM-5: Diagnostic and Statistical Manual, 5th edition 








Functional Cognitive Disorder (FCD) refers to complaints of persistent problematic cognitive 
difficulties, when accompanied by positive features termed “internal inconsistency” (see Text 
Box 1), and which are not better explained by another disorder e.g., a neurodegenerative 
disease process (see Text Box 2 for full FCD criteria). This is relevant to all clinicians to whom 
such patients present, including in general practice, gerontology, neurology, psychiatry and 
others. FCD is likely common but is rarely diagnosed, perhaps in part because such patients 
usually concurrently meet descriptive criteria for either Mild Cognitive Impairment (MCI), or 
Subjective Cognitive Decline (SCD). MCI is a syndrome involving objective cognitive decline 
greater than expected for age, that does not interfere with activities of daily life (Albert et al., 
2011). SCD describes subjective concern regarding decline in cognitive abilities without 
evidence of objective cognitive deficit (Howard, 2020; Jessen et al., 2020). Conceptually, both 
SCD and MCI are heterogeneous concepts and include people with a variety of underlying 
causes (Blackburn et al., 2014), including neurodegenerative diseases, medical or psychiatric 
diagnoses, medication and alcohol or other recreational drug effects, and FCD. See Figure 1 
for an illustration. However, in practice, the majority of research involving MCI and/ or SCD 
has been predicated on a linear progression from SCD through MCI to dementia, which is 
problematic if most of these patients do not in fact have underlying neurodegenerative disease.  
Biomarkers that predict Alzheimer’s pathology in particular, or neurodegeneration more 
generally (including but not limited to MR and PET imaging, genetics, and blood or CSF 
measurement of amyloid, tau and neurofilament) are already finding utility in clinical trials and 
are increasingly used in clinical practice. However, while biomarkers may provide evidence 
for or against a diagnosis of Alzheimer’s disease, a positive diagnosis of FCD on clinical 
grounds has a number of potentially important complementary roles. First, patients with FCD 
are likely to benefit from distinct strategies to help with their symptoms. Second, having FCD 
may prove to be an important exclusion criterion for clinical trials, or may need to be taken 
into account when interpreting the results of trials targeting Alzheimer’s pathology to reduce 
heterogeneity. Thirdly, since a dual diagnosis of FCD, and cognitive impairment secondary to 
Alzheimer’s pathology, is entirely possible (indeed such dual diagnoses are common in other 




Alzheimer’s pathology. And finally, as we move to diagnosing patients ever earlier, 
communicating biomarker results may precipitate FCD in people who would otherwise not 
have manifest symptoms for some time.  
Patients with FCD are increasingly prevalent in tertiary memory clinics (comprising 12-56% 
of new referrals) (Elsey et al., 2015; Wakefield et al., 2018) (Pennington et al., 2015a; 
Bharambe and Larner, 2018a; Bhome et al., 2019a; Pennington et al., 2019). Different case 
definitions may explain how some FCD case series score predominantly normally on objective 
cognitive testing, whereas others underperform or demonstrate inconsistencies in some areas 
of objective testing. Note that symptoms in FCD are not feigned. Where tested, patients with 
functional disorders do not consistently fail tests of Performance Validity or “effort”, but may 
display impaired selective attention (Teodoro et al., 2018). We encounter many patients who 
pass performance validity testing but score greater than two standard deviations below normal 
on standardised cognitive testing (i.e., falling into the FCD/MCI overlap area on Figure 1). 
Population-based identification of MCI cases may over-recruit people with FCD, as they may 
be younger, more aware of research opportunities and more open to recruitment efforts.  
 
De-emphasising the inevitable expectation of progression (from SCD to MCI to 
Alzheimer’s dementia) 
Understanding the prodromal phase of dementia is clearly of great importance for elucidation 
of causal mechanisms and development of novel interventions for Alzheimer’s pathology. 
However, a substantial proportion of people with MCI will later return to normal cognitive 
function, or maintain stable cognition, rather than showing progressive deterioration. 
Neuropathological analyses of cohorts who met MCI criteria before death show they are 
intermediate between those with normal cognition and those with dementia (Stephan et al., 
2012). In highlighting such associations, few reports focus on the substantial proportion of 
individuals with MCI whose brains are histologically normal (Schneider et al., 2009; Abner et 
al., 2017). It is also difficult to define a clear boundary between age-normative 
neuropathological changes and the burden of neurodegeneration which is required for cognitive 
impairment (Ferrer, 2012). There are many reasons why autopsy studies might miss very early 
neurodegeneration, such as subtle or not-yet-understood pathologies, varying degrees of 
immunohistochemical analysis and regional brain sampling (Nelson et al., 2012). Regardless, 




brain pathology. In addition, many people with demonstrable neuropathological changes 
associated with Alzheimer’s disease identified after death did not experience cognitive 
symptoms in life (Latimer et al., 2017), raising the possibility that only a proportion of the 
cognitive symptoms experienced by those with neuropathology, might be caused by that 
pathology. 
There is clearly a biological trajectory in Alzheimer’s disease, with the clinical syndrome 
usually preceded by an MCI phase (Jack et al., 2010). However, it is important not to 
extrapolate this backwards to assume that all or most people with MCI are on this trajectory en 
route to dementia, because this downplays the importance of other (including FCD) 
explanations for MCI. Many studies emphasise “conversion” to dementia (e.g., Annualised 
Conversion Rates of MCI to dementia), which implies a deterministic relationship between 
MCI and Alzheimer’s dementia (as well as implying an abrupt step-change). Biomarkers are 
increasingly being used to identify risk of clinical progression on an individual basis (van 
Maurik et al., 2019) but are as yet imperfect and not always available; and in general there 
tends to be less focus on the causes of cognitive symptoms in those who do not progress to 
dementia. A population based analysis that tracked these changes over 7 years, found that 53% 
remained as MCI cases, while 35% reverted to normal cognition (Ganguli et al., 2019).  A 
default assumption that neurodegeneration underlies MCI may be reinforced amongst 
clinicians and researchers who frequently interact with people affected by established dementia 
(i.e., people who have passed through MCI as part of a neurodegenerative trajectory). In the 
wider population however, and especially in older people, other non-neurodegenerative 
aetiologies and multifactorial processes are likely to contribute significantly (Petersen et al., 
2014). Figure 2 (adapted from (McWhirter et al., 2019)) illustrates how heterogeneous 
trajectories in FCD can account for some of the above mentioned discrepancy.  Assumptions 
of progression may also contribute to widespread public anxiety regarding the inevitability of 
dementia. 
 
Diagnosis and aetiology of FCD 
Typical clinical presentations of FCD most commonly focus around memory impairment 
(often alongside attention and concentration difficulties), often in the form of “memory 
perfectionism” and mnestic block (Pennington et al., 2015b).  FCD less often involves non-




suggest the typical age at onset of FCD is mid-life (therefore overlapping with early-onset 
neurodegeneration) (Pennington et al., 2015a; Bharambe and Larner, 2018a; Wakefield et al., 
2018), but this may in part reflect the composition of specialist clinics, with referral patterns 
influenced by  the increased likelihood of neurodegeneration in older ages. As with people in 
the prodromal stage of neurodegenerative dementia, those with FCD are often understandably 
anxious about their symptoms, are able to discuss their difficulties and coping strategies, and 
can display mild but persistent deficits (including those seen on objective standardised 
cognitive tests, or as observed by others in the general course of life), with few other clinical 
signs.  
FCD definitions still lack consensus, hindering our understanding of prevalence particularly in 
community settings (Stone et al., 2015), and hindering wider understanding and acceptance of 
the diagnosis.  Diagnostic difficulty around FCD exists for several reasons. Firstly, the presence 
of mnestic concern, and the cognitive trajectory over the short term, may look similar across 
FCD and early neurodegeneration. Secondly, there is frequently co-occurrence of functional 
cognitive symptoms alongside some combination of neurodegeneration, general medical, 
psychiatric or surgical problems, or drug toxicity. In this context, the functional symptoms may 
be secondary, in the form of a “functional overlay”, although in the clinic setting it is often 
difficult to differentiate this from the background cognitive symptoms due to identified 
comorbidities (including substances used). Unfortunately, this distinction is not aided by 
research studies that often exclude people with mental health conditions, despite their being 
very common in memory clinic.  Thirdly, FCD symptoms often persist over time (Schmidtke 
et al., 2008), so for example will still feature in MCI studies that check for the persistence of 
symptoms. Longer-term outcomes of FCD have not been thoroughly studied, although the 
default assumption should be that affected individuals have the same chance of later developing 
neurodegeneration as the background population (without such an occurrence indicating a 
“missed” earlier diagnosis of neurodegeneration). However, this does require empirical testing, 
because in certain contexts FCD could arise as a prodrome to neurodegeneration (as has been 
found with certain presentations of late life anxiety, depression and Mild Behavioural 
Impairment (Livingston et al., 2017; Creese et al., 2019)).  These difficulties, and the recent 
entry of FCD into the cognitive diagnostic lexicon, likely explain why FCD is rarely diagnosed, 
despite its likely frequency, given the high prevalence of other functional neurological 




In addition to under-diagnosis due to diagnostic difficulty, some clinicians will be using other 
terms for the same condition in different settings (Blackburn et al., 2014; Bailey et al., 2017). 
Also, some clinicians may be avoiding naming the condition at all, or fall back on classifying 
the patient as either SCD or MCI (which are descriptive rather than aetiological categories). 
Some practitioners use the term “worried well”, presumably as a means of identifying a group 
of individuals whose symptoms aren’t due to underlying neurodegeneration. This is 
unsatisfactory to patients, who are generally not reassured when told their symptoms have no 
underlying pathological basis, but aren’t offered an alternative explanation. It also hinders 
efforts to positively identify a distinct group. The situation is improving with diagnostic 
systems e.g., DSM-5 (American Psychiatric Association, 2013), recently switching to 
emphasise positive criteria for diagnosis rather than identifying Functional Neurological 
Disorder (FND) solely by the absence of neurological, psychiatric or other general medical 
explanatory causes.  
Here, we propose an operational definition for FCD (Text box 2), which we hope will enable 
clearer communication in the clinical setting, and standardisation for research purposes. This 
definition is in line with the DSM-5 definition of FND1. The key to diagnosing FCD is 
identifying positive evidence of internal inconsistency (see Text Box 1). However, we have 
also included a list of mimics (Text Box 3) – situations with a flavour of internal inconsistency 
but that should prompt consideration of alternative diagnoses. We recognise this is a changing 
field; these criteria represent a work in progress. 
It is important to note that DSM-5 FND includes only sensory and motor (not cognitive) 
phenotypes. We envisage FCD as the equivalent cognitive phenotype (and we would 
recommend DSM to consider this in their next revision). Placing FCD within the broader FND 
umbrella recognises the phenotypic overlap across functional disorders, which includes 
similarities in neurocognitive profiles (Teodoro et al., 2018). Thus the “cognitive fog” often 
described by patients with functional movement disorder or dissociative seizures can be 
conceptualised as part of the same broad condition. Although our mechanistic understanding 
of FND is incomplete, it is notable that neurobiological models of FND make no distinction 
 
1 We also considered whether FCD could fit within DSM-5’s Somatic Symptom Disorder (SSD). 
However, SSD does not actually capture elements of FCD that we feel are integral (i.e., internal 
inconsistency), so does nothing to aetiologically disentangle FCD from prodromal Alzheimer’s 
disease (which can involve similar levels of anxiety). SSD also does not account for those with FCD 





between the mechanism of different symptom types. Motor, sensory, cognitive and 
interoceptive symptoms can all conceivably arise from the same basic malfunction proposed 
to occur in FND, which is entirely consistent with the common co-occurrence of multiple 
functional symptoms in the same individual (Edwards et al., 2012; Van den Bergh et al., 2017).  
We also feel DSM’s “associated features supporting diagnosis” for FND generally apply to 
FCD in particular, namely: a history of multiple somatic symptoms; stress or trauma at onset; 
and dissociative symptoms (though none of these features are necessary for diagnosis, and 
absence should not lead to the diagnosis being withheld). Finally, we also feel it is helpful to 
include a specifier for presence or absence of any comorbidity that is linked to the cognitive 
symptoms. A non-exhaustive list includes health anxiety, mild Traumatic Brain Injury (mTBI), 
depression, fibromyalgia or Alzheimer’s pathology. Such comorbidities can influence the way 
people with FCD present, and the types of interventions they might respond to. As an 
illustration, systematic reviews have suggested that whilst mTBI is sometimes accompanied by 
temporary effects on attention, processing speed and memory, there is evidence of good 
recovery beyond the initial weeks and months (Carroll et al., 2014; Cassidy et al., 2014). This 
makes it possible that many of the self-reported symptoms outside this time frame may have a 
functional disorder aetiology. The situation is often clarified by the clinician’s re-assessment 
of the reported severity of the head injury and surrounding circumstances; a Cognitive 
Behavioural Therapy framework is often helpful to understand how expectations may drive 
behavioural responses to the injury (van Gils et al., 2020). An operational definition of FCD 
provides the opportunity for the TBI field to quantify the prevalence of a functional component 
to cognitive symptomatology. 
In cognitive clinics, patients with FCD are typically encountered following symptom duration 
of at least six months. However, there is no clear need to wait for this duration before making 
an FCD diagnosis if positive indicators are present. Recent-onset cases may be harder to 
diagnose than persistent cases, and this would alter the differential diagnosis. It would also be 
important to avoid over-diagnosis of short-lived forgetting that is within the normal human 
experience. However, substantial clinical benefit could be gained from making and 
communicating an FCD diagnosis early, rather than subjecting the patient to prolonged 
diagnostic limbo.  
Substantial heterogeneity in severity can be seen within FCD, as illustrated in Figures 1 and 2. 




definition of one of SCD, MCI or dementia. However, these purely descriptive classifications 
should be used with great caution (regardless of suspected underlying aetiology). This is 
because they have come to be associated with progressive neuropathology; if, however, the 
cognitive presentation is being driven by a functional disorder, then greater impairment does 
not have the same implications regarding irreversible progression.  The adoption of a definition 
for FCD opens the door to testing whether an “FCD subtype of MCI” would contribute to 
sample stratification in biomarker or intervention studies, and  also aid communication of likely 
outcome and potential treatment. 
A diagnosis of FCD would be excluded if another condition better accounted for the symptoms, 
such as cognitive symptoms that occur as part of a depressive episode, sometimes termed 
“depressive pseudo-dementia”. The temporal relationship, severity of depression, and the 
pattern of impairments can inform this distinction. Note that cognitive symptoms may not 
resolve on depressive episode resolution (Rock et al., 2014). Of patients referred to a tertiary 
neuropsychiatry clinic, half of those meeting FCD criteria had co-morbid depression (and 
therefore half did not) (Bhome et al., 2019a). In addition, subthreshold generalised anxiety 
disorder, dysthymia, and obsessive-compulsive personality traits are commonly noted and 
appear to be aetiologically relevant in many cases. We hope that our definition can enable 
research to better quantify rates and relevance of comorbidities and other external factors, in 
FCD and in comparison to those in other groups (such as healthy controls, and those with early 
neurodegeneration). Patients with functional disorders often find themselves falling between 
different specialties, and individual clinicians often feel they are not best placed to offer 
management. We consider that clinicians working in all specialties that diagnose cognitive 
disorders should have the skills to recognise FCD, and can play an important part in its 
management (e.g., (Carson et al., 2016)). Heterogeneity within FCD means that some patients 
may be relatively straightforward to identify, and management should begin with an 
explanation of the symptoms and giving a positive diagnosis; others may require referral 
tailored to unravelling a diagnostic challenge; and others may be best managed within a mental 
health model.  
 
Better appreciation of FCD would enhance outcomes across the cognitive field 
Research is ongoing to identify positive features in clinical assessment that point to a functional 




helpful to transparently discuss these internal inconsistencies and their implications with the 
patient (Stone and Edwards, 2012). These features can also be used to form testable hypotheses. 
For example, we could predict that amongst people with cognitive symptoms, those displaying 
internal inconsistency would be: 
• More likely to respond to certain treatments (e.g., treatments to modify metacognition) 
• More likely to remain stable or improve their cognitive scores, and less likely to 
eventually develop dementia 
• Less likely to have biomarkers of Alzheimer’s or global neurodegeneration.  
It may actually be easier to identify those who meet criteria for FCD, than those who have 
underlying Alzheimer’s pathology, due to the limited access and imperfect precision of current 
Alzheimer’s biomarkers. In other words, neurodegeneration clinical trial candidates should not 
just meet SCD or MCI criteria, but also lack the positive features of functional cognitive 
conditions, in order to enhance power to detect effective Alzheimer’s disease modifiers. On the 
other hand, to understand processes and efficacy at the population level, particularly in the 
older age bracket, it may be more appropriate to use dimensional scales (rather than exclusions) 
to quantify the separate effects of comorbidities, drug toxicity, psychological and lifestyle 
factors, and FCD. 
Improving our identification of key characteristics of FCD, and the many often-interwoven 
aetiologies behind MCI, should simultaneously improve identification of those who are in the 
prodromal stage of neurodegeneration. Doing so requires thorough assessment of other likely 
aetiological contributors, as well as examining patterns of “reversion” as well as “conversion”. 
This could provide greater signal relative to noise, both in understanding biological processes 
of neurodegeneration, and in testing interventions. Establishing FCD as an essential axis in 
cognitive assessment will help us to better understand, and ultimately modify, the causes of 
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Figure 1: Where FCD fits in relation to other key terminology used in the cognitive clinic. 
“Objective cognitive impairment” denotes low scores on standardized testing. “Subjective 
cognitive concern” denotes an individual’s perception of their cognitive difficulties (note some 
patients with MCI and dementia lack insight). Patients with FCD account for a proportion of 
those with MCI, and a proportion of those with SCD; rarely, those with FCD can meet criteria 
for dementia (i.e., severe enough to interfere with daily function and independence). Crosses 
represent biomarkers for neurodegenerative conditions. Biomarkers are clustered most densely 
among people with dementia; a small number of true positive biomarkers also exist in the 
healthy population with neither subjective concerns nor objective impairment (indicating 
neurodegenerative tendency that has not yet manifest), and some will be false positives because 
a biomarker with 100% specificity seems unlikely (see (McWhirter et al., 2019) for further 
discussion). 
 
Figure 2: Trajectories in FCD (after (McWhirter et al., 2019)). This illustrates the wide 
spectrum of potential trajectories within FCD, highlighting that some patients have 
considerable persisting symptoms and impairment even after serial testing, whereas others 
return to baseline functioning. The causes of these divergent trajectories may be explicable via 
comorbidities or external factors, but often no such factors are identified. Disentangling this 
heterogeneity is an important area for future research. The x axis represents each lifetime; those 
who remain above the x-axis to the end of their lifetime have died from other causes. 
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Text Box 1: Internal Inconsistency 
Internal inconsistency is the ability to perform a task well at certain times, but with significantly 
impaired ability at other times, particularly when the task is the focus of attention. Therefore, 
the individual components required to execute the task are intact, but there is difficulty 
engaging them at the appropriate intensity or duration on demand2. This may reflect differences 
in automatic versus explicit processing. This is not the same as simple fluctuation over time, 
which can be consistent with many other processes (such as delirium, Lewy body disease, etc). 
Finally, internal inconsistency needs to be demonstrated within a particular cognitive domain. 
Do not superficially take a cognitive screen summary score in the normal or mild range, plus a 
patient with significant day-to-day impairment, to conclude this is FCD (rather, this should be 
a starting point for exploring the particular cause of the day-to-day impairment). 
Positive evidence of cognitive internal inconsistency can be demonstrated through any of the 
following: 
• Where subjectively-reported cognitive difficulties, and/or low standardised cognitive test 
scores, directly contrast with:  
• Conversational abilities observed during interview (Alexander et al., 2019) 
• Reported activities, such as being involved in a cognitively demanding occupation; or 
difficulties only occurring in particular situations 
• Collateral history suggesting concern is significantly higher in the individual than their 
supporter (including the “attended alone” sign e.g., (Bharambe and Larner, 2018b) 
• Specific patterns within neuropsychological testing that indicate cognitive processes 
performing better when accessed less explicitly, e.g., greater ability in delayed recall than 
initial registration of information. 
 
2 We also considered whether a patient’s tendency to give “approximate answers” should be used as an 
example of internal inconsistency. This tendency, the so-called Ganser syndrome, is poorly characterized in the 
literature, and care should be taken over what counts as an “approximate” versus a “wrong” answer. The key 
focus should be on a patient demonstrating normal and abnormal performance on the same cognitive ability, 
without there being other mitigating factors that intervene (e.g., fluctuations in consciousness, psychiatric 





Where examples such as the above are elicited, part of the diagnostic process should include 
pointing them out to the patient, and explaining that they demonstrate a temporary block to 
accessing memories, rather than a persistent memory defect. 
 
Research is ongoing to investigate whether impaired meta-cognition (the ability to reflect on 
and monitor cognitive processes) may contribute to cognitive internal inconsistency (Bhome 
et al., 2019).  
 
Text Box 2: Diagnostic criteria for Functional Neurological Disorder – Cognitive Subtype 
1. One or more symptoms of impaired cognitive function 
2. Clinical evidence of internal inconsistencyA  
3. Symptoms or deficit that are not better explained by another medical or psychiatric 
disorderB 
4. Symptoms or deficit that cause clinically significant distress or impairmentC in social, 
occupational, or other important areas of functioning, or warrants medical evaluation. 
A See text box 1 
B Patients may have comorbid medical or psychiatric disorder as well as FCD  
CTo aid reliability for neurodegenerative research purposes, a minimum of 6 months duration 
should be considered (see text).  
Specify if: With/ without a linked comorbidity (see text).  
Text Box 3: Red flags to prompt consideration of diagnoses other than FCD (and why) 
FCD is common and most clinicians who interact with patients with cognitive difficulties 
should be confident at identifying it. It is important not to medicalize normal human 
experience, for example where cognitive concerns are found in the absence of objective deficit, 
and where this is not associated with distress nor impairment. The following are some features 
that should prompt consideration of certain differential diagnoses. 
• Internal inconsistency needs to be demonstrated within a particular cognitive domain. 
This is because certain other disorders of mind or brain can allow normal performance on 
simple testing, while disrupting daily activities that require subtly different cognitive domains, 
such as:   
• Greater difficulty understanding single words than the superficially more complex task 
of whole sentence comprehension (this is a feature of semantic dementia) 
• Difficulties pertaining primarily to visual comprehension (Posterior Cortical Atrophy 
can produce difficulties that mimic internal inconsistency, including the reverse size 
phenomenon, and perception of moving versus static objects (Crutch et al., 2012)) 
• Apathy or low mood can also cause discrepancy between real-world behaviour and 




to “Where did you go on holiday” receiving a sparse response such as “Provence” 
without the patient being able to move from this to spontaneously generate more 
specific information; yet he can, on direct questioning, recall specific events once these 
are mentioned by his wife. 
• Intact implicit memory with defective conscious memory, can occur in conditions such 
as Korsakoff’s psychosis 
• Difficulties greater on recognition than on recall, may be a consequence of damage to 
perirhinal or parahippocampal areas (Eichenbaum et al., 2007) 
• Difficulty in real-word executive functioning out of proportion to superficial pencil-
and-paper testing, can be a feature of dorsolateral prefrontal damage.  
• Long term temporal pattern: absence of decline, or fluctuation over months or years. 
Such a pattern indicates incongruity with neurodegeneration, but by itself is not a positive 
identifier for FCD, since other processes could cause this.    
• Variability day-to-day should lead to consideration of conditions such as obstructive 
sleep apnoea, delirium or Lewy Body Disease (if other appropriate features are present). 
Typically patients with these conditions would not display normal and abnormal 
performance on similar tasks within a single consultation.  
• Sudden onset and persistence should lead to consideration of stroke syndromes. 
Semantic access dyslexia is a left-hemisphere stroke syndrome that typically causes 
inconsistency in identifying the same semantic stimulus presented multiple times (this 
is distinct from semantic dementia, in which the semantic concepts are consistently 
non-retrievable) (Mirman and Britt, 2014) 
• Finally, have a higher suspicion for neurodegeneration if the presentation is non-
mnestic, particularly since early-onset Alzheimer’s disease has relatively more non-mnestic 
presentations (Koedam et al., 2010). 
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